Etienne G, Faberes C, Bauduer F, et al. - This study was undertaken to investigate the rate of patients eligible for tyrosine kinase inhibitors (TKI) discontinuation and molecular recurrence-free survival (MRFS) after stop according to recommendations. Researchers enrolled newly diagnosed chronic-phase chronic myeloid leukemia (CP-CML) patients who were treated with first-line TKI in the nine French participating centers over a 10-year period. Furthermore, eligibility to treatment discontinuation and MRFS were examined and matched according to selection criteria defined by recommendations and first-line treatments. For this study, 398 patients were considered between January 2006 and December 2015. The results showed that one-third of CP-CML patients treated with TKI frontline fulfilled the selection criteria implied by European LeukemiaNet treatment-free remission recommendations. It was shown that meeting selection criteria and second-generation TKI frontline were correlated with the highest MRFS.